CervoMed Inc. (CRVO)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
CRVO data show neflamapimod reverses DLB brain atrophy and improves function
# 📄 What This Document Is 📰 This filing is a press release announcing significant new scientific data presented by CervoMed Inc. (NASDAQ: CRVO) at the 2026 AAN Annual Meeting in Chicago. This document details the results from the RewinD-LB Phase 2b clinical trial, focusing on the drug neflamapimod
CervoMed Inc. — 8-K Filing
# 📢 What This Document Is This is an 8-K filing, which is like a company's official "news flash" to the stock market. CervoMed is using it to announce that it will be presenting major updates about its key drug, neflamapimod, at important medical conferences. It's a way to build credibility and sha
SEC filings
All filings →Insider trades
All insider trades →CervoMed Inc. has no reported insider trades in the last 90 days.